Clinical Trial

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2024 (before its estimated November 9, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-03.
Trial Details
NCT Number NCT06117566
Lead Sponsor Shanghai Jiatan Pharmatech Co., Ltd
Conditions Solid Tumor
Enrollment 100 participants
Start Date 2022-11-18
Primary Completion 2025-11-09 (estimated)
Study Completion 2025-11-09 (estimated)
Updated on ClinicalTrials.gov 2024-11-25